Iman Adibi

Dr. Iman Adibi

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Research in Medical Sciences
Verified
Journal Article
Open access
PDF file
IAIman Adibi
Iman Adibi
MSMehdi Sanayei
Mehdi Sanayei
FTFarinaz Tabibian
Farinaz Tabibian
NRNeda Ramezani
Neda Ramezani
APAhmad Pourmohammadi
Ahmad Pourmohammadi
KAKiarash Azimzadeh
Kiarash Azimzadeh
Fatigue is the most common symptom in multiple sclerosis (MS). Although MS-related fatigue (MS-F) strongly affects quality of life and social performance of patients, there is currently a lack of knowledge about its pathophysiology, which in turns leads to poor objective diagnosis and management. Recent studies have attempted to explain potential etiologies as well as treatments for MS-F. However, it seems that without a consensus on its nature, these data could not provide a route to a successful approach. In this Article, we review definitions, epidemiology, risk factors and correlated comorbidities, pathophysiology, assessment methods, neuroimaging findings, and pharmacological and nonpharmacological treatments of MS-F. Further studies are warranted to define fatigue in MS patients more accurately, which could result in precise diagnosis and management.

9 March 2022 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
APAhmad Pourmohammadi
Ahmad Pourmohammadi
RRRoya Riahi
Roya Riahi
SHSayed Mohsen Hosseini
Sayed Mohsen Hosseini
IAIman Adibi
Iman Adibi

5 July 2022 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
Ali MotahharyniaAli Motahharynia
Ali Motahharynia
SNSaba Naghavi
Saba Naghavi
VSVahid Shaygannejad
Vahid Shaygannejad
IAIman Adibi
Iman Adibi

13 November 2022 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
APAhmad Pourmohammadi
Ahmad Pourmohammadi
Ali MotahharyniaAli Motahharynia
Ali Motahharynia
VSVahid Shaygannejad
Vahid Shaygannejad
FAFereshteh Ashtari
Fereshteh Ashtari
IAIman Adibi
Iman Adibi
MSMehdi Sanayei
Mehdi Sanayei

10 August 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FTFarinaz Tabibian
Farinaz Tabibian
KAKiarash Azimzadeh
Kiarash Azimzadeh
VSVahid Shaygannejad
Vahid Shaygannejad
FAFereshteh Ashtari
Fereshteh Ashtari
IAIman Adibi
Iman Adibi
MSMehdi Sanayei
Mehdi Sanayei
Behavioral aspects and underlying pathology of attention deficit in multiple sclerosis (MS) remain unknown. This study aimed to clarify impairment of attention and its relationship with MS-related fatigue. Thirty-four relapse-remitting MS (RRMS), 35 secondary-progressive MS (SPMS) and 45 healthy controls (HC) were included. Results of psychophysics tasks (attention network test (ANT) and Posner spatial cueing test) and fatigue assessments (visual analogue scale and modified fatigue impact scale (MFIS)) were compared between groups. In ANT, attentional network effects were not different between MS phenotypes and HC. In Posner task, RRMS or SPMS patients did not benefit from valid cues unlike HC. RRMS and SPMS patients had less gain in exogenous trials with 62.5 ms cue-target interval time (CTIT) and endogenous trials with 250 ms CTIT, respectively. Total MFIS was the predictor of gain in 250 ms endogenous blocks and cognitive MFIS predicted orienting attentional effect. Executive attentional effect in RRMS patients with shorter disease duration and orienting attentional effect in longer diagnosed SPMS were correlated with MFIS scores. The pattern of attention deficit in MS differs between phenotypes. Exogenous attention is impaired in RRMS patients while SPMS patients have deficit in endogenous attention. Fatigue trait predicts impairment of endogenous and orienting attention in MS.

30 January 2021 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
SNSaba Naghavi
Saba Naghavi
APAhmad Pourmohammadi
Ahmad Pourmohammadi
IAIman Adibi
Iman Adibi
Protein S deficiency is a thrombophilia associated with an increased risk of thromboembolism. Previous studies have shown its role as a predisposing factor for venous thromboembolism, but its role in recurrent arterial ischemic stroke remains uncertain. Here we report a patient with recurrent ischemic stroke due to protein S deficiency. Oral anticoagulant treatment with vitamin K antagonist (VKA) drugs is used to treat and prevent thromboembolic events caused by thrombophilia, but it has many limitations, especially in the case of recurrent thromboembolic events. Direct oral anticoagulants (DOACs) have many advantages over VKA. Previous studies have shown that they are safe in cases of thrombophilia, but they are not well studied in recurrent ischemic stroke due to protein S deficiency. In this study our patient was treated with rivaroxaban. Protein S deficiency may be a predisposing factor in recurrent ischemic stroke, and rivaroxaban can be a safe and effective treatment option. Further studies are needed to confirm our findings.